
CHA HPMC’s Southern California Eye Institute, which is participating in the study, has state-of-the-art facilities for patient care, research and innovation. (photo courtesy of Southern California Eye Institute)
CHA Hollywood Presbyterian Medical Center, a member of CHA Health Systems, is participating in a $40.5-million multisite study for the development of the Asian Cohort for Alzheimer’s Disease. The study is funded by a grant from the National Institute on Aging.
CHA HPMC’s Southern California Eye Institute is among 15 academic medical centers across the United States and Canada participating in the study led by Penn Medicine. Alzheimer’s disease poses a significant public health challenge, with increasing prevalence among aging populations worldwide. Limited data exists on its impact on people of Asian descent.
“This collaboration presents an incredible opportunity to address the significant research gaps that exist regarding Alzheimer’s disease in the Asian community in the United States and Canada and we are honored to be selected as a participating site. By studying a diverse cohort of Asian individuals, we can enhance our understanding of the disease, identify potential risk factors and develop tailored interventions and treatments to improve patient outcomes,” said Dr. Rohit Varma, chief medical officer of CHA HPMC, founding director of SCEI and site principal investigator for the study.
Led by Li-San Wang, professor of pathology and laboratory medicine in the Perelman School of Medicine at the University of Pennsylvania, the project represents the first major Alzheimer’s disease genetics cohort for Asian Americans and Asian Canadians. ACAD is recruiting adults ages 60 and older, with or without cognitive issues, with Korean, Vietnamese and Chinese ancestry. Participants are asked to complete a lifestyle and demographic questionnaire, undergo a cognitive assessment and provide a saliva and optional blood sample. The research team, which includes international leaders in Alzheimer’s disease, genetics and epidemiology, will analyze the genetic data from the samples to identify risk variants in the Asian American and Asian Canadian populations, compared to other populations and to those living in Asia. The goal is to develop blood biomarker benchmarks and a polygenic risk score model to measure the risk for Alzheimer’s disease among Asian Americans and Asian Canadians.
CHA HPMC’s selection in the ACAD project is a testament to its commitment to addressing the unique healthcare needs of diverse communities and ensuring that all ethnic groups have equal access to care, administrators said.
“We are fully dedicated to the success of this prestigious study and contributing our expertise, resources and state-of-the-art facilities to drive the study,” Varma said.
The grant builds on a two-year, National Institute on Aging-funded pilot grant awarded in September 2020 to assess the feasibility of the ACAD study design. As of May 2023, more than 1,800 individuals have joined the list for the study, with 713 formally consenting to enroll. The goal is to expand enrollment and recruit at least 5,000 participants over five years.
CHA Hollywood Presbyterian Medical Center is located at 1300 N. Vermont Ave. For information, visit hollywoodpresbyterian.com.









0 Comment